BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17620005)

  • 1. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
    Manickavasagam S; Ye Y; Lin Y; Perez-Polo RJ; Huang MH; Lui CY; Hughes MG; McAdoo DJ; Uretsky BF; Birnbaum Y
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):321-30. PubMed ID: 17620005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination.
    Ye Y; Lin Y; Perez-Polo R; Huang MH; Hughes MG; McAdoo DJ; Manickavasagam S; Uretsky BF; Birnbaum Y
    Am J Physiol Heart Circ Physiol; 2007 Jul; 293(1):H813-8. PubMed ID: 17416607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin.
    Rosanio S; Ye Y; Atar S; Rahman AM; Freeberg SY; Huang MH; Uretsky BF; Birnbaum Y
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):27-36. PubMed ID: 16435070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation.
    Merla R; Ye Y; Lin Y; Manickavasagam S; Huang MH; Perez-Polo RJ; Uretsky BF; Birnbaum Y
    Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1918-28. PubMed ID: 17616749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat.
    Ye Y; Abu Said GH; Lin Y; Manickavasagam S; Hughes MG; McAdoo DJ; Perez-Polo RJ; Birnbaum Y
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):275-82. PubMed ID: 18327703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury.
    Birnbaum Y; Ye Y; Rosanio S; Tavackoli S; Hu ZY; Schwarz ER; Uretsky BF
    Cardiovasc Res; 2005 Feb; 65(2):345-55. PubMed ID: 15639473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
    Ye Y; Lin Y; Atar S; Huang MH; Perez-Polo JR; Uretsky BF; Birnbaum Y
    Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1158-69. PubMed ID: 16603698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury.
    Bi XY; He X; Zhao M; Yu XJ; Zang WJ
    J Cardiovasc Pharmacol; 2013 May; 61(5):391-400. PubMed ID: 23364605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
    Birnbaum Y; Castillo AC; Qian J; Ling S; Ye H; Perez-Polo JR; Bajaj M; Ye Y
    Cardiovasc Drugs Ther; 2012 Dec; 26(6):445-56. PubMed ID: 22936458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
    Ye Y; Martinez JD; Perez-Polo RJ; Lin Y; Uretsky BF; Birnbaum Y
    Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H343-51. PubMed ID: 18469150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?
    Mensah K; Mocanu MM; Yellon DM
    J Am Coll Cardiol; 2005 Apr; 45(8):1287-91. PubMed ID: 15837263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide.
    Gonon AT; Widegren U; Bulhak A; Salehzadeh F; Persson J; Sjöquist PO; Pernow J
    Cardiovasc Res; 2008 Apr; 78(1):116-22. PubMed ID: 18222959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2.
    Atar S; Ye Y; Lin Y; Freeberg SY; Nishi SP; Rosanio S; Huang MH; Uretsky BF; Perez-Polo JR; Birnbaum Y
    Am J Physiol Heart Circ Physiol; 2006 May; 290(5):H1960-8. PubMed ID: 16339820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism.
    Hashimoto A; Miyakoda G; Hirose Y; Mori T
    Atherosclerosis; 2006 Dec; 189(2):350-7. PubMed ID: 16545819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
    Birnbaum Y; Lin Y; Ye Y; Martinez JD; Huang MH; Lui CY; Perez-Polo JR; Uretsky BF
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2891-7. PubMed ID: 17277020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
    Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats.
    Fan Y; Yang S; Zhang X; Cao Y; Huang Y
    Clin Exp Pharmacol Physiol; 2012 Nov; 39(11):938-43. PubMed ID: 23106693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acute and chronic atorvastatin on cardioprotection of ischemic postconditioning in isolated rat hearts.
    Fan Y; Yang S; Cao Y; Huang Y
    Cardiovasc Ther; 2013 Aug; 31(4):187-92. PubMed ID: 22954178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin preconditioning attenuates liver ischemia reperfusion injury through the phosphatidylinositol-3 kinase/AKT/endothelial nitric oxide synthase pathway.
    Fu W; Liao X; Ruan J; Li X; Chen L; Wang B; Wang K; Zhou J
    J Surg Res; 2013 Aug; 183(2):876-84. PubMed ID: 23490139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKA-mediated eNOS phosphorylation in the protection of ischemic preconditioning against no-reflow.
    Li XD; Cheng YT; Yang YJ; Meng XM; Zhao JL; Zhang HT; Wu YJ; You SJ; Wu YL
    Microvasc Res; 2012 Jul; 84(1):44-54. PubMed ID: 22542438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.